Prelude Therapeutics Inc
Research Prelude Therapeutics Inc (PRLD) on Bullrun: market cap USD 524.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRLD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 524.86M
- Financial periodQ1 2026
- RevenueUSD 4.58M
- Net income-USD 77.80M
- Free cash flow-USD 43.78M
Valuation Snapshot
latest market cap is USD 524.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 12.14M | -USD 99.50M | -USD 56.37M | n/a | -1.29 | USD 35.26M | USD 17.79M | USD 68.64M |
| FY2024 | USD 7.00M | -USD 127.17M | -USD 103.65M | n/a | -1.68 | USD 12.47M | USD 18.03M | USD 131.46M |
| FY2023 | n/a | -USD 121.83M | -USD 110.58M | n/a | -2.02 | USD 25.29M | USD 16.89M | USD 237.09M |
| FY2022 | n/a | -USD 115.44M | -USD 86.75M | n/a | -2.44 | USD 30.61M | USD 1.82M | USD 195.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 524.86M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 182.57M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 70.04M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 234.13M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 289.07M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 592.65M | n/a | n/a | n/a |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Prelude Therapeutics Inc's market cap?
Prelude Therapeutics Inc's market capitalization is USD 524.86M.
What does Prelude Therapeutics Inc do?
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.